Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
MNTA's Cash to Debt is ranked higher than
99% of the 789 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. MNTA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MNTA' s Cash to Debt Range Over the Past 10 Years
Min: 10.74  Med: 119.91 Max: No Debt
Current: No Debt
Equity to Asset 0.80
MNTA's Equity to Asset is ranked higher than
79% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MNTA: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
MNTA' s Equity to Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.86 Max: 0.96
Current: 0.8
-0.49
0.96
Interest Coverage No Debt
MNTA's Interest Coverage is ranked higher than
99% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.15 vs. MNTA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MNTA' s Interest Coverage Range Over the Past 10 Years
Min: 110.84  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 5.89
M-Score: -0.41
WACC vs ROIC
14.22%
-801.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -96.02
MNTA's Operating margin (%) is ranked lower than
86% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.25 vs. MNTA: -96.02 )
Ranked among companies with meaningful Operating margin (%) only.
MNTA' s Operating margin (%) Range Over the Past 10 Years
Min: -448.33  Med: -249.62 Max: 63.48
Current: -96.02
-448.33
63.48
Net-margin (%) -93.75
MNTA's Net-margin (%) is ranked lower than
86% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. MNTA: -93.75 )
Ranked among companies with meaningful Net-margin (%) only.
MNTA' s Net-margin (%) Range Over the Past 10 Years
Min: -429.9  Med: -247.2 Max: 63.71
Current: -93.75
-429.9
63.71
ROE (%) -25.83
MNTA's ROE (%) is ranked lower than
81% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.55 vs. MNTA: -25.83 )
Ranked among companies with meaningful ROE (%) only.
MNTA' s ROE (%) Range Over the Past 10 Years
Min: -66.11  Med: -32.35 Max: 59.21
Current: -25.83
-66.11
59.21
ROA (%) -21.53
MNTA's ROA (%) is ranked lower than
81% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. MNTA: -21.53 )
Ranked among companies with meaningful ROA (%) only.
MNTA' s ROA (%) Range Over the Past 10 Years
Min: -51.08  Med: -28.38 Max: 55.62
Current: -21.53
-51.08
55.62
ROC (Joel Greenblatt) (%) -423.11
MNTA's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.88 vs. MNTA: -423.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MNTA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -592.17  Med: -415.9 Max: 349.83
Current: -423.11
-592.17
349.83
Revenue Growth (3Y)(%) 3.80
MNTA's Revenue Growth (3Y)(%) is ranked lower than
56% of the 609 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. MNTA: 3.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MNTA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.5 Max: 139.6
Current: 3.8
0
139.6
EBITDA Growth (3Y)(%) 4.80
MNTA's EBITDA Growth (3Y)(%) is ranked lower than
58% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.60 vs. MNTA: 4.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MNTA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.2  Med: -7 Max: 30.4
Current: 4.8
-45.2
30.4
EPS Growth (3Y)(%) 4.40
MNTA's EPS Growth (3Y)(%) is ranked lower than
55% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. MNTA: 4.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MNTA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.2  Med: -9 Max: 30.1
Current: 4.4
-48.2
30.1
» MNTA's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-08-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MNTA Guru Trades in Q4 2015

John Paulson 21,800 sh (New)
Jim Simons 550,586 sh (+25.60%)
PRIMECAP Management 2,738,900 sh (+1.41%)
Paul Tudor Jones Sold Out
Joel Greenblatt 29,242 sh (-0.37%)
» More
Q1 2016

MNTA Guru Trades in Q1 2016

Jim Simons 1,029,051 sh (+86.90%)
PRIMECAP Management 2,738,900 sh (unchged)
Joel Greenblatt Sold Out
John Paulson Sold Out
» More
Q2 2016

MNTA Guru Trades in Q2 2016

PRIMECAP Management 2,738,900 sh (unchged)
Jim Simons 364,670 sh (-64.56%)
» More
Q3 2016

MNTA Guru Trades in Q3 2016

Paul Tudor Jones 19,731 sh (New)
PRIMECAP Management 2,739,900 sh (+0.04%)
Jim Simons 292,800 sh (-19.71%)
» More
» Details

Insider Trades

Latest Guru Trades with MNTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325414    SIC: 2836
Compare:NYSE:DPLO, OTCPK:KHTRF, NAS:SGYP, NAS:AMPH, NAS:IPXL, NAS:SUPN, NYSE:LCI, OTCPK:NPPNY, OTCPK:EVTCY, NAS:PCRX, NAS:EGRX, NAS:DEPO, NAS:SCMP, NAS:HRTX, NAS:ACET, NAS:SCLN, NAS:FLXN, NAS:COLL, NAS:KPTI, NAS:ADMS » details
Traded in other countries:LZ1.Germany,
Momenta Pharmaceuticals Inc is a biotechnology company. It is engaged in developing generic versions of complex drugs, biosimilars and novel therapeutics for oncology and autoimmune disease.

Momenta Pharmaceuticals Inc was incorporated in the state of Delaware in May 2001 under the name of Mimeon, Inc., later changed the name Momenta Pharmaceuticals, Inc. in September 2002. The Company is a biotechnology company operating in three product areas: Complex Generics, Biosimilars and Novel therapeutics. In Complex Generics product area, the Company develops generic versions of complex drugs that were approved by the United States Food and Drug Administration under New Drug Applications. Enoxaparin Sodium Injection is the Company's first product to receive marketing approval under ANDA. The second complex generic product candidate, M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a complex drug consisting of a synthetic mixture of polypeptide chains. In Biosimilars product area, the Company is seeking to develop biosimilar versions of biologic medicines that were approved by the FDA under Biologics License Applications. Biologics are complex mixtures, and the Company unlocks their structural subtleties using an approach that is similar to the one it uses in the development of complex generics. Novel Drugs program uses the established characterization and process engineering capabilities from complex generics and biosimilars programs with a focus on polysaccharides and therapeutic proteins. Momenta were originally founded to develop novel drugs and it remains the long term goal for the Company. As with the complex generics and biosimilars the Company's platform gives a detailed understanding of the complex structures of novel product candidates, their associated manufacturing processes and controls, and the targeted biologic systems. The Company license or own a patent portfolio of over 100 patent families, each of which includes United States patent applications and/or issued patents as well as foreign counterparts. The Company relies on contract manufacturers since it does not own facilities for manufacturing any products.

Top Ranked Articles about Momenta Pharmaceuticals Inc

Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar Humira and M923 show equivalent results in moderate-to-severe chronic plaque psoriasis patients
Momenta Pharmaceuticals (NASDAQ:MNTA) announced yesterday that the results from the “confirmatory, randomized, double-blind, multicenter study of M923 in adult patients with moderate-to-severe chronic plaque psoriasis” are equivalent to AbbVie's (NYSE:ABBV) Humira in terms of the therapy’s efficacy, safety and body’s immune response after a treatment period of 16 weeks. Read more...

Ratios

vs
industry
vs
history
P/B 3.34
MNTA's P/B is ranked lower than
54% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. MNTA: 3.34 )
Ranked among companies with meaningful P/B only.
MNTA' s P/B Range Over the Past 10 Years
Min: 1.34  Med: 3.02 Max: 13.69
Current: 3.34
1.34
13.69
P/S 10.47
MNTA's P/S is ranked lower than
81% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. MNTA: 10.47 )
Ranked among companies with meaningful P/S only.
MNTA' s P/S Range Over the Past 10 Years
Min: 1.83  Med: 15.14 Max: 55.5
Current: 10.47
1.83
55.5
Current Ratio 7.46
MNTA's Current Ratio is ranked higher than
86% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. MNTA: 7.46 )
Ranked among companies with meaningful Current Ratio only.
MNTA' s Current Ratio Range Over the Past 10 Years
Min: 4.39  Med: 11.04 Max: 28.87
Current: 7.46
4.39
28.87
Quick Ratio 7.46
MNTA's Quick Ratio is ranked higher than
88% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. MNTA: 7.46 )
Ranked among companies with meaningful Quick Ratio only.
MNTA' s Quick Ratio Range Over the Past 10 Years
Min: 4.39  Med: 11.04 Max: 28.87
Current: 7.46
4.39
28.87
Days Sales Outstanding 170.72
MNTA's Days Sales Outstanding is ranked lower than
90% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.78 vs. MNTA: 170.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNTA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.32  Med: 78.92 Max: 170.72
Current: 170.72
36.32
170.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.10
MNTA's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 435 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.60 vs. MNTA: -10.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNTA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -218.2  Med: -10.1 Max: -1.7
Current: -10.1
-218.2
-1.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.69
MNTA's Price/Net Cash is ranked higher than
78% of the 210 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.40 vs. MNTA: 4.69 )
Ranked among companies with meaningful Price/Net Cash only.
MNTA' s Price/Net Cash Range Over the Past 10 Years
Min: 2.03  Med: 4.02 Max: 14.33
Current: 4.69
2.03
14.33
Price/Net Current Asset Value 3.83
MNTA's Price/Net Current Asset Value is ranked higher than
78% of the 468 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.66 vs. MNTA: 3.83 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MNTA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.55  Med: 3.6 Max: 11.36
Current: 3.83
1.55
11.36
Price/Tangible Book 3.30
MNTA's Price/Tangible Book is ranked higher than
55% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. MNTA: 3.30 )
Ranked among companies with meaningful Price/Tangible Book only.
MNTA' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.5  Med: 3.1 Max: 10.13
Current: 3.3
1.5
10.13
Price/Projected FCF 6.42
MNTA's Price/Projected FCF is ranked lower than
70% of the 307 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.77 vs. MNTA: 6.42 )
Ranked among companies with meaningful Price/Projected FCF only.
MNTA' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.77  Med: 3.69 Max: 8.31
Current: 6.42
1.77
8.31
Price/Median PS Value 0.68
MNTA's Price/Median PS Value is ranked higher than
87% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. MNTA: 0.68 )
Ranked among companies with meaningful Price/Median PS Value only.
MNTA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 1.02 Max: 3.05
Current: 0.68
0.12
3.05
Earnings Yield (Greenblatt) (%) -12.09
MNTA's Earnings Yield (Greenblatt) (%) is ranked lower than
86% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. MNTA: -12.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MNTA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -13.5  Med: 26.6 Max: 78.3
Current: -12.09
-13.5
78.3

More Statistics

Revenue (TTM) (Mil) $97.82
EPS (TTM) $ -1.36
Beta1.58
Short Percentage of Float8.10%
52-Week Range $7.86 - 16.95
Shares Outstanding (Mil)71.02

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 99 152 175 198
EPS ($) -1.35 -0.72 -1.00 0.68
EPS w/o NRI ($) -1.35 -0.72 -1.00 0.68
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MNTA

Headlines

Articles On GuruFocus.com
Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar Nov 30 2016 
Very Low P/E Stocks Joel Greenblatt selected Dec 22 2011 
Momenta Pharmaceuticals Inc. (MNTA) SVP, CFO Richard P Shea sells 979 Shares Feb 24 2011 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 45,296 Shares Aug 05 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 7,800 Shares Mar 12 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 32,200 Shares Mar 10 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 1,413 Shares Mar 03 2010 

More From Other Websites
Is Momenta Pharmaceuticals, Inc. (MNTA) A Good Stock To Buy? Dec 07 2016
Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar Nov 30 2016
Company News for November 30, 2016 Nov 30 2016
Momenta/Shire's Humira Biosimilar Meets Study Objective Nov 30 2016
MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Other Events Nov 29 2016
Momenta stock jumps nearly 10% on positive late-stage results for Humira biosimilar Nov 29 2016
Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923, a Proposed HUMIRA®... Nov 29 2016
ETFs with exposure to Momenta Pharmaceuticals, Inc. : November 23, 2016 Nov 23 2016
Medtronic, Patterson Among Day's Biggest Losers, Trump Continues to Pressure Healthcare Sector Nov 22 2016
Coverage initiated on Momenta Pharma by Aegis Capital Nov 22 2016
Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18,... Nov 18 2016
Momenta Pharmaceuticals Announces Publication on the Design of M230, a Novel Autoimmune Disease Drug... Nov 17 2016
Morgan Stanley Cuts Teva's Price Target By 33% Nov 16 2016
Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US :... Nov 11 2016
MOMENTA PHARMACEUTICALS INC Financials Nov 10 2016
MOMENTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)